| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset for CHB, ALG-000184, a capsid assembly modulator, is progressing through Phase I clinical trials. Additionally, Aligos is advancing ALG-020572, an …
Over the last 12 months, insiders at Aligos Therapeutics, Inc. have bought $0 and sold $0 worth of Aligos Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Aligos Therapeutics, Inc. have bought $6M and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 7,933,601 shares for transaction amount of $6M was made by Nuechterlein Carole () on 2023‑10‑25.
| 2023-10-25 | Nuechterlein Carole | 7.93M 22.4566% | $0.76 | $6M | +4.10% | |||
| 2020-10-20 | Vivo Capital VIII, LLC | 10 percent owner | 550,000 1.9863% | $15.00 | $8.25M | +61.44% | ||
| 2020-10-20 | Novo Holdings A/S | 10 percent owner | 200,000 0.7223% | $15.00 | $3M | +61.44% | ||
| 2020-10-20 | Woiwode Thomas | director | 200,000 0.7223% | $15.00 | $3M | +61.44% | ||
| 2020-10-20 | Versant Venture Capital VI, L.P. | director | 400,000 1.4446% | $15.00 | $6M | +61.44% |
| Nuechterlein Carole | 11025941 176.5688% | $52.37M | 1 | 0 | +4.1% | |
| Vivo Capital VIII, LLC | 10 percent owner | 3116658 49.91% | $14.8M | 1 | 0 | +61.44% |
| Novo Holdings A/S | 10 percent owner | 2614563 41.8695% | $12.42M | 1 | 0 | +61.44% |
| Woiwode Thomas | director | 862444 13.8111% | $4.1M | 1 | 0 | +61.44% |
| Versant Venture Capital VI, L.P. | director | 862444 13.8111% | $4.1M | 1 | 0 | +61.44% |
$2,542,362 | 111 | 11.81% | $36.83M | |
$156,891,025 | 80 | -24.91% | $36.3M | |
$84,911,583 | 59 | 17.82% | $37.44M | |
$6,204,522 | 45 | 1.91% | $36.5M | |
$931,435 | 28 | 16.31% | $24.8M |
| Increased Positions | 22 | +61.11% | 750,143 | +28.29% |
| Decreased Positions | 12 | -33.33% | 590,230 | -22.26% |
| New Positions | 13 | New | 568,995 | New |
| Sold Out Positions | 5 | Sold Out | 383,728 | Sold Out |
| Total Postitions | 46 | +27.78% | 3M | +6.03% |
| Woodline Partners Lp | $4,275.00 | 9.36% | 468,199 | -50,101 | -9.67% | 2025-09-30 |
| Deep Track Capital, Lp | $4,055.00 | 8.88% | 444,110 | 0 | 0% | 2025-09-30 |
| Alyeska Investment Group, L.P. | $3,762.00 | 8.24% | 412,000 | 0 | 0% | 2025-09-30 |
| Sio Capital Management, Llc | $3,067.00 | 6.72% | 335,937 | 0 | 0% | 2025-09-30 |
| Readystate Asset Management Lp | $1,854.00 | 4.06% | 203,113 | +66,331 | +48.49% | 2025-09-30 |
| Vanguard Group Inc | $1,568.00 | 3.43% | 171,689 | +31,913 | +22.83% | 2025-09-30 |
| Adage Capital Partners Gp, L.L.C. | $1,278.00 | 2.8% | 140,000 | 0 | 0% | 2025-09-30 |
| Baker Bros. Advisors Lp | $758.00 | 1.66% | 83,055 | 0 | 0% | 2025-09-30 |
| Hhlr Advisors, Ltd. | $696.00 | 1.53% | 76,247 | 0 | 0% | 2025-09-30 |
| Lpl Financial Llc | $503.00 | 1.1% | 55,120 | +25,020 | +83.12% | 2025-09-30 |